These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 30689565

  • 21. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
    Kaplow J, Vandijck M, Gray J, Kanekiyo M, Huyck E, Traynham CJ, Esquivel R, Fagan AM, Luthman J.
    Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216
    [Abstract] [Full Text] [Related]

  • 22. Circular RNA expression profile of Alzheimer's disease and its clinical significance as biomarkers for the disease risk and progression.
    Li Y, Fan H, Sun J, Ni M, Zhang L, Chen C, Hong X, Fang F, Zhang W, Ma P.
    Int J Biochem Cell Biol; 2020 Jun; 123():105747. PubMed ID: 32315771
    [Abstract] [Full Text] [Related]

  • 23. Amyloid β42 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death.
    Ribbe M, Kern S, Börjesson Hansson A, Östling S, Zetterberg H, Blennow K, Skoog I.
    Dement Geriatr Cogn Disord; 2019 Jun; 47(1-2):114-124. PubMed ID: 30970371
    [Abstract] [Full Text] [Related]

  • 24. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
    Reijs BLR, Ramakers IHGB, Elias-Sonnenschein L, Teunissen CE, Koel-Simmelink M, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Johannsen P, Vanderstichele H, Verhey F, Devanand DP, Visser PJ.
    J Alzheimers Dis; 2017 Jun; 60(3):1025-1034. PubMed ID: 28984603
    [Abstract] [Full Text] [Related]

  • 25. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM.
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [Abstract] [Full Text] [Related]

  • 26. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D.
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.
    Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
    [Abstract] [Full Text] [Related]

  • 28. Apo-Eε4 allele in conjunction with Aβ42 and tau in CSF: biomarker for Alzheimer's disease.
    Kandimalla RJ, Prabhakar S, Binukumar BK, Wani WY, Gupta N, Sharma DR, Sunkaria A, Grover VK, Bhardwaj N, Jain K, Gill KD.
    Curr Alzheimer Res; 2011 Mar; 8(2):187-96. PubMed ID: 21222606
    [Abstract] [Full Text] [Related]

  • 29. Diabetes mellitus contributes to higher cerebrospinal fluid tau levels selectively in Alzheimer's disease patients with the APOE4 genotype.
    Motta C, Assogna M, Bonomi CG, Mascolo AP, De Lucia V, Semprini R, Mercuri NB, Koch G, Martorana A.
    Eur J Neurol; 2021 Dec; 28(12):3965-3971. PubMed ID: 34309155
    [Abstract] [Full Text] [Related]

  • 30. CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease.
    Boumenir A, Cognat E, Sabia S, Hourregue C, Lilamand M, Dugravot A, Bouaziz-Amar E, Laplanche JL, Hugon J, Singh-Manoux A, Paquet C, Dumurgier J.
    Alzheimers Res Ther; 2019 Mar 28; 11(1):29. PubMed ID: 30922415
    [Abstract] [Full Text] [Related]

  • 31. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Öhrfelt A, Blennow K, Hardy J, Schott J, Mills K, Zetterberg H.
    Mol Neurodegener; 2016 Jan 12; 11():3. PubMed ID: 26754172
    [Abstract] [Full Text] [Related]

  • 32. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW.
    Alzheimers Res Ther; 2019 Oct 10; 11(1):83. PubMed ID: 31601267
    [Abstract] [Full Text] [Related]

  • 33. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
    Geijselaers SLC, Aalten P, Ramakers IHGB, De Deyn PP, Heijboer AC, Koek HL, OldeRikkert MGM, Papma JM, Reesink FE, Smits LL, Stehouwer CDA, Teunissen CE, Verhey FRJ, van der Flier WM, Biessels GJ, Parelsnoer Institute Neurodegenerative Diseases study group.
    J Alzheimers Dis; 2018 Oct 10; 61(1):309-320. PubMed ID: 29154275
    [Abstract] [Full Text] [Related]

  • 34. Odor identification score as an alternative method for early identification of amyloidogenesis in Alzheimer's disease.
    Igeta Y, Hemmi I, Yuyama K, Ouchi Y.
    Sci Rep; 2024 Feb 26; 14(1):4658. PubMed ID: 38409432
    [Abstract] [Full Text] [Related]

  • 35. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease.
    Jingami N, Asada-Utsugi M, Uemura K, Noto R, Takahashi M, Ozaki A, Kihara T, Kageyama T, Takahashi R, Shimohama S, Kinoshita A.
    J Alzheimers Dis; 2015 Feb 26; 45(1):109-15. PubMed ID: 25428256
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years.
    Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O.
    J Alzheimers Dis; 2010 Feb 26; 21(4):1119-28. PubMed ID: 21504133
    [Abstract] [Full Text] [Related]

  • 37. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.
    Pan C, Korff A, Galasko D, Ginghina C, Peskind E, Li G, Quinn J, Montine TJ, Cain K, Shi M, Zhang J.
    J Alzheimers Dis; 2015 Feb 26; 45(3):709-19. PubMed ID: 25613100
    [Abstract] [Full Text] [Related]

  • 38. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.
    Yakushev I, Muller MJ, Buchholz HG, Lang U, Rossmann H, Hampel H, Schreckenberger M, Fellgiebel A.
    Curr Alzheimer Res; 2012 Feb 26; 9(2):241-7. PubMed ID: 22044023
    [Abstract] [Full Text] [Related]

  • 39. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.
    J Alzheimers Dis; 2016 Feb 26; 51(4):1069-83. PubMed ID: 26923009
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C, Perestelo-Pérez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P.
    J Alzheimers Dis; 2014 Feb 26; 42(3):777-88. PubMed ID: 24916543
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.